Table 2 Immunomodulatory therapy.
| Patient | Previous IMT | Concomitant medication | Time to control inflammation (weeks) | Adverse effects | Treatment status |
|---|---|---|---|---|---|
| 1 | MM, MTX, INF | MM, MTX, CLX, PF | 2 | None | Ongoing |
| 2 | MTX, ETP | MTX, PF | 3.3 | None | Ongoing |
| 3 | MM, MTX, CSA, ETP | MM | 4.3 | None | Ongoing |
| 4 | MTX, CSA | CSA, PF | 1.7 | None | Ongoing |
| 5 | MTX, ETP | MTX, MM, PF | 8.6 | None | Ongoing |
| 6 | MM, CSA | PF, BFC | 4.7 | Elevated LFT* | Ongoing |
| 7 | MTX | MM, PF | 3.7 | Nausea | Discontinued |
| 8 | None | MTX, PF | 20 | Elevated LFT* | Ongoing |
| 9 | MTX | MM, PF | 45 | None | Ongoing |
| 10 | MTX | MM | 2 | None | Ongoing |
| 11 | MM | MTX, PRED, PF, BFC | 5.9 | None | Ongoing |
| 12 | None | MTX, PF | 7 | None | Remission |
| 13 | MTX | MM, LE | 7.3 | None | Ongoing |
| 14 | CSA, MM | PF | 4.3 | None | Ongoing |
| 15 | MTX, MM | MTX, MM, PF | 9.7 | None | Ongoing |
| 16 | MM, ETP | MM, PF | 4.3 | Leukopenia* | Ongoing |
| 17 | MTX, CHL | MTX, MEL | 5.3 | None | Ongoing |
| 18 | MTX, ETP | MM, CSA, PF, ATO | 12.3 | None | Ongoing |
| 19 | MTX, CSA, AZA | RIM | 25 | Leukopenia* | Remission |
| 20 | MTX, CSA, MM, CHL | PF, IV MPD | 46.3 | Fatigue, myalgia | Remission |
| 21 | MM, CSA, SIR | MM, CSA, SIR, PF | 6.4 | Nausea | Ongoing |
| 22 | MTX, MM | MM, PRED, PF, BFC | 8 | Leukopenia* | Ongoing |
| 23 | MTX, MM, CSA | None | 3.4 | Leukopenia* | Ongoing |
ATO, Atropine 1% drops; AZA, azathioprine; BFC, bromfenac 0.09%; CHL, chlorambucil; CLX, celecoxib; CSA, cyclosporine; ETP, etanercept; INF, infliximab; IV MPD, intravenous methylprednosolone; LE, loteprednol etabonate 0.5% drops; LFT, liver function test; MEL, meloxicam; MM, mycophenolate mofetil; MTX, methotrexate; PF, prednisolone 1%; PRED, oral prednisone; RIM, rimexolone 1%, SIR, sirolimus. *Transient.